NEKTAR THERAPEUTICS
For the period ended Dec 31, 2025. Filed Mar 13, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 13, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits and Financial Statement Schedules
(a)
The following documents are filed as part of this report:
(1)
Consolidated Financial Statements:
The following financial statements are filed as part of this Annual Report on Form 10-K under Item 8 “Financial Statements and Supplementary Data.”
| Page | |
|---|---|
| Report of Independent Registered Public Accounting Firm (PCAOB ID: 42) | 64 |
| Consolidated Balance Sheets at December 31, 2025 and 2024 | 66 |
| Consolidated Statements of Operations for each of the two years in the period ended December 31, 2025 | 67 |
| Consolidated Statements of Comprehensive Loss for each of the two years in the period ended December 31, 2025 | 68 |
| Consolidated Statements of Stockholders’ Equity for each of the two years in the period ended December 31, 2025 | 69 |
| Consolidated Statements of Cash Flows for each of the two years in the period ended December 31, 2025 | 70 |
| Notes to Consolidated Financial Statements | 71 |
(2)
Financial Statement Schedules:
All financial statement schedules have been omitted because they are not applicable, or the information required is presented in our consolidated financial statements and notes thereto under Item 8 of this Annual Report on Form 10-K.
(3)
Exhibits.
Except as so indicated in Exhibit 32.1, the following exhibits are filed as part of, or incorporated by reference into, this Annual Report on Form 10-K.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.